Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

被引：41

作者：

Furuya, Naoki

Fukuhara, Tatsuro

Saito, Haruhiro

Watanabe, Kana

Sugawara, Shunichi

Iwasawa, Shunichiro

Tsunezuka, Yoshio

Yamaguchi, Ou

Okada, Morihito

Yoshimori, Kouzou

Nakachi, Ichiro

Gemma, Akihiko

Azuma, Koichi

Hagiwara, Koichi

Nukiwa, Toshihiro

Morita, Satoshi

Kobayashi, Kunihiko

Maemondo, Makoto

机构：

[1] St Marianna Univ, Div Resp Med, Dept Internal Med, Sch Med, Kawasaki, Kanagawa, Japan

[2] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan

[3] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[4] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[5] Chiba Univ Hosp, Dept Med Oncol, Chiba, Japan

[6] Ishikawa Prefectural Cent Hosp, Dept Gen Thorac Surg, Kanazawa, Ishikawa, Japan

[7] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[8] Hiroshima Univ, Dept Surg Oncol, Hiroshima, Japan

[9] JATA, Fukujuji Hosp, Ctr Clin Canc, Tokyo, Japan

[10] Saiseikai Utsunomiya Hosp, Div Pulm, Internal Med, Utsunomiya, Tochigi, Japan

[11] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan

[12] Kurume Univ Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[13] Jichi Med Univ, Div Pulm Med, Dept Internal Med, Shimotsuke, Tochigi, Japan

[14] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan

[15] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[16] Iwate Med Univ, Morioka, Iwate, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9006

引用

页数：1